GoAI
Get started
OncoTherapy Science, Inc. logo

OncoTherapy Science, Inc.

4564.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥21.00

¥0.00 · 0.00%

Aug 24, 3:30 PM JST

4564.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Junichi Shimada
Listed since
Sep 29, 2005
Employees
46

Market position

Day range

Current ¥21.00

52-week range

Current ¥21.00

Open
¥21.00
Previous close
¥21.00
Volume
220.34M
1.27× average
Average volume
173.91M
Average daily volume
Market cap
8.37B JPY
Beta
0.28
Market reference 1
50-day average
¥19.76
+6.28% above average
200-day average
¥21.325
-1.52% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-8.9×
P/B (TTM)
3.57×
P/S (TTM)
10.76×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
2.19%
Operating margin
-106.36%
Net margin
-113.81%

Financial health

Debt / equity
0×
Altman Z-score
4.16
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends33%-60%-153%-246%Gross margin, FY2021: 9.87%Gross margin, FY2022: 3.67%Gross margin, FY2023: -29.13%Gross margin, FY2024: -1.70%Gross margin, FY2025: 1.73%Operating margin, FY2021: -177.92%Operating margin, FY2022: -97.49%Operating margin, FY2023: -183.70%Operating margin, FY2024: -106.38%Operating margin, FY2025: -100.23%Net margin, FY2021: -222.90%Net margin, FY2022: -98.57%Net margin, FY2023: -211.13%Net margin, FY2024: -108.70%Net margin, FY2025: -112.63%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 9.87%. Gross margin FY2022 3.67%. Gross margin FY2023 -29.13%. Gross margin FY2024 -1.70%. Gross margin FY2025 1.73%. Operating margin FY2021 -177.92%. Operating margin FY2022 -97.49%. Operating margin FY2023 -183.70%. Operating margin FY2024 -106.38%. Operating margin FY2025 -100.23%. Net margin FY2021 -222.90%. Net margin FY2022 -98.57%. Net margin FY2023 -211.13%. Net margin FY2024 -108.70%. Net margin FY2025 -112.63%.

Income trends

Revenue

808.53M JPY+7.80%

Operating income

−810.38M JPY-1.56%

Net income

−910.64M JPY-11.70%
Income trends across reported periods1.53B JPY36.1M JPY−1.45B JPY−2.94B JPYRevenue, FY2021: 1.15B JPYRevenue, FY2022: 1.13B JPYRevenue, FY2023: 610.12M JPYRevenue, FY2024: 750.05M JPYRevenue, FY2025: 808.53M JPYOperating income, FY2021: −2.05B JPYOperating income, FY2022: −1.11B JPYOperating income, FY2023: −1.12B JPYOperating income, FY2024: −797.94M JPYOperating income, FY2025: −810.38M JPYNet income, FY2021: −2.57B JPYNet income, FY2022: −1.12B JPYNet income, FY2023: −1.29B JPYNet income, FY2024: −815.29M JPYNet income, FY2025: −910.64M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.15B JPY. Revenue FY2022 1.13B JPY. Revenue FY2023 610.12M JPY. Revenue FY2024 750.05M JPY. Revenue FY2025 808.53M JPY. Operating income FY2021 −2.05B JPY. Operating income FY2022 −1.11B JPY. Operating income FY2023 −1.12B JPY. Operating income FY2024 −797.94M JPY. Operating income FY2025 −810.38M JPY. Net income FY2021 −2.57B JPY. Net income FY2022 −1.12B JPY. Net income FY2023 −1.29B JPY. Net income FY2024 −815.29M JPY. Net income FY2025 −910.64M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue808.53M JPY750.05M JPY610.12M JPY1.13B JPY1.15B JPY
Cost of goods sold794.57M JPY762.8M JPY787.84M JPY1.09B JPY1.04B JPY
Gross profit13.96M JPY−12.76M JPY−177.72M JPY41.69M JPY113.91M JPY
Research and development534.94M JPY491.11M JPY678.05M JPY716.46M JPY1.73B JPY
Selling, general, and administrative289.41M JPY294.07M JPY265.03M JPY431.64M JPY436.28M JPY
Operating expenses824.35M JPY785.18M JPY943.08M JPY1.15B JPY2.17B JPY
Interest income66K JPY751K JPY—218K JPY146K JPY
Interest expense1.31M JPY1.2M JPY218K JPY——
Depreciation and amortization—797M JPY2K JPY16M JPY16.54M JPY
Operating income−810.38M JPY−797.94M JPY−1.12B JPY−1.11B JPY−2.05B JPY
Net income−910.64M JPY−815.29M JPY−1.29B JPY−1.12B JPY−2.57B JPY

Company facts updated Aug 24, 2026.

4564.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥6,987

—

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,797

—

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,895

—

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,210

—

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,858

—

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,406.5

—

Continue in GoAI

Research 4564.T

research.disclaimer